Literature DB >> 27668059

Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2016        PMID: 27668059      PMCID: PMC5013849     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


× No keyword cloud information.
  13 in total

1.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.

Authors:  Christopher P Cannon; Benjamin A Steinberg; Sabina A Murphy; Jessica L Mega; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2006-07-12       Impact factor: 24.094

2.  Genetics: a gene of rare effect.

Authors:  Stephen S Hall
Journal:  Nature       Date:  2013-04-11       Impact factor: 49.962

3.  Inhibition of intestinal cholesterol absorption by ezetimibe in humans.

Authors:  Thomas Sudhop; Dieter Lütjohann; Annette Kodal; Michael Igel; Diane L Tribble; Sukrut Shah; Inna Perevozskaya; Klaus von Bergmann
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

4.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Authors:  Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

5.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

6.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

7.  Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Authors:  Gregory G Schwartz; Anders G Olsson; Markus Abt; Christie M Ballantyne; Philip J Barter; Jochen Brumm; Bernard R Chaitman; Ingar M Holme; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Hardi Mundl; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; R Scott Wright
Journal:  N Engl J Med       Date:  2012-11-05       Impact factor: 91.245

8.  PCSK9: a convertase that coordinates LDL catabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  J Lipid Res       Date:  2008-11-19       Impact factor: 5.922

9.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  3 in total

1.  Evaluation of the Effectiveness and Safety of Alirocumab Use in Statin-Intolerant Veterans.

Authors:  Fiona I Imarhia; Elisabeth M Sulaica; Tyler Varisco; Marcy Pilate
Journal:  Fed Pract       Date:  2021-11

2.  Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells.

Authors:  Xuan Ni; Zhuang-Zhuang Yang; Ling-Qun Ye; Xing-Long Han; Dan-Dan Zhao; Feng-Yue Ding; Nan Ding; Hong-Chun Wu; Miao Yu; Guang-Yin Xu; Zhen-Ao Zhao; Wei Lei; Shi-Jun Hu
Journal:  Acta Pharmacol Sin       Date:  2021-03-08       Impact factor: 7.169

Review 3.  The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus.

Authors:  Isabella Bonilha; Eric Hajduch; Beatriz Luchiari; Wilson Nadruz; Wilfried Le Goff; Andrei C Sposito
Journal:  Metabolites       Date:  2021-11-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.